Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK early access to medicines scheme (EAMS)

Alan Jones*, Katherine Peers, Anthony Wierzbicki, Radha Ramachandran, Michael Mansfield, Charlotte Dawson, Antonio Ocho-Ferraro, Handrean Soran, Fiona Jenkinson, Ian McDowell, Paul Downie, Paul Hamilton, Richard Jones

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background and aims
The VOL4002 study assessed the efficacy and safety of volanesorsen in 22 adults with genetically confirmed familial chylomicronaemia syndrome (FCS) treated in the UK Early Access to Medicines Scheme (EAMS), with (“prior exposure”) or without (“treatment naive”) previous treatment in the APPROACH and/or APPROACH-OLE volanesorsen phase 3 studies.
Methods
Data collection focusing on triglyceride (TG) level and platelet counts and pancreatitis events. Pancreatitis incidence during volanesorsen treatment was compared against the 5-year period preceding volanesorsen exposure. Volanesorsen 285 mg was self-administered subcutaneously once every 2 weeks.
Results
Individual patient volanesorsen exposure ranged from 6 to 51 months (total cumulative exposure, 589 months). Among treatment-naive patients (n = 12), volanesorsen treatment resulted in an averaged median 52% reduction (−10.6 mmol/L) from baseline (26.4 mmol/L) in TG levels at 3 months, which were maintained through time points over 15 months of treatment (47%–55% reductions). Similarly, prior-exposure patients (n = 10) experienced a 51% reduction (−17.8 mmol/L) from pre-treatment baseline (28.0 mmol/L), with reductions of 10%–38% over 21 months of treatment. A comparison of pancreatitis event rates found a 74% reduction from the 5-year period before (one event/2.8 years) and during (one event/11.0 years) volanesorsen treatment. Platelet declines were consistent with observations in phase 3 clinical trials. No patient recorded a platelet count Conclusions
This longitudinal study supports the efficacy of volanesorsen in patients with FCS for lowering TG levels over treatment periods up to 51 months with no apparent safety signals related to increased duration of exposure.
Original languageEnglish
JournalAtherosclerosis
Early online date15 May 2023
DOIs
Publication statusEarly online date - 15 May 2023

Fingerprint

Dive into the research topics of 'Long-term effects of volanesorsen on triglycerides and pancreatitis in patients with familial chylomicronaemia syndrome (FCS) in the UK early access to medicines scheme (EAMS)'. Together they form a unique fingerprint.

Cite this